GPX4 and non-small cell lung carcinoma: Additionally, in vivo experiments demonstrated that propofol suppressed tumor growth and decreased cisplatin resistance by enhancing the expression of these microRNAs and inhibiting GPX4, reinforcing its potential as a therapeutic option for NSCLC (Han et al., 2023).